ArriVent BioPharma (AVBP) Balance Sheet: Assets & Liabilities

ArriVent BioPharma (AVBP) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), ArriVent BioPharma reported total assets of $333.17M and total liabilities of $25.95M. Shareholders' equity was $307.22M, up 19.2% from $257.65M a year earlier. Total debt stood at $14.00K against $312.82M in cash and short-term investments, a net cash position of $312.81M. That puts debt-to-equity at 0.00, compared with 0.00 a year earlier.

ArriVent BioPharma Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for ArriVent BioPharma, Inc. (AVBP) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Current Assets
Cash and Cash Equivalents	45.54	74.29	150.39	163.37	37.28
Short-Term Investments	267.28	144.57	0.00	0.00	0.00
Cash & Short-Term Investments	312.82	218.86	150.39	163.37	37.28
Accounts Receivable	0.06	0.50	0.76	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00
Other Current Assets	20.08	7.62	9.58	19.25	5.67
Total Current Assets	332.90	226.98	159.97	182.62	42.95
Non-Current Assets
Property, Plant & Equipment (Net)	0.01	0.15	0.29	0.14	0.00
Long-Term Investments	0.00	47.68	0.00	0.00	0.00
Other Non-Current Assets	0.26	0.13	2.84	0.07	0.09
Total Non-Current Assets	0.27	47.96	3.13	0.21	0.09
Total Assets	333.17	274.94	163.10	182.83	43.04
Current Liabilities
Accounts Payable	5.93	3.78	4.53	3.09	0.29
Short-Term Debt	0.01	0.16	0.14	0.13	0.00
Accrued Liabilities	20.00	13.33	6.95	2.46	0.61
Other Current Liabilities	20.00	13.33	6.95	5.14	1.53
Total Current Liabilities	25.95	17.27	11.62	8.36	1.82
Non-Current Liabilities
Long-Term Debt	0.00	0.01	0.18	0.01	0.00
Other Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00
Total Non-Current Liabilities	0.00	0.01	0.18	0.01	0.00
Total Liabilities	25.95	17.29	11.80	8.37	1.82
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-404.64	-238.33	-157.85	-88.51	-51.61
Accumulated Other Comprehensive Income	0.01	-0.21	0.00	0.00	0.00
Additional Paid-in Capital	711.85	496.20	4.65	3.40	2.96
Shares Outstanding	42.45	33.71	31.96	31.96	31.96
Total Stockholders' Equity	307.22	257.65	151.30	174.46	41.22
Total Liabilities & Equity	333.17	274.94	163.10	182.83	43.04

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About ArriVent BioPharma Balance Sheet

How much debt does ArriVent BioPharma have?

ArriVent BioPharma had total debt of $14.00K as of Dec 31, 2025, against $312.82M in cash and short-term investments. Its debt-to-equity ratio was 0.00. Total debt was $176.00K a year earlier.

What are ArriVent BioPharma's total assets?

ArriVent BioPharma reported total assets of $333.17M as of Dec 31, 2025, up 21.2% from $274.94M a year earlier. Total liabilities were $25.95M.

What is ArriVent BioPharma's shareholders' equity?

ArriVent BioPharma's shareholders' equity was $307.22M as of Dec 31, 2025, or about $7.24 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition